IQVIA Holdings Inc. (IQV) — Analysis Summary
IQVIA Holdings Inc. (IQV) has a market cap of $43.19B with year-over-year revenue growth of +5.9%. Net margin stands at 8.3%. The stock trades at a P/E ratio of 31.2.
Key Takeaways
- Revenue changed +5.9% year-over-year
- Net margin of 8.3%
- P/E ratio of 31.2
Compared to other companies in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector, IQV posted revenue growth of +5.9% and trades at a P/E of 31.2.
IQVIA Holdings Inc. (IQV)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 4.7x — elevated leverage
Interest coverage at 2.9x — limited headroom for earnings decline
Current ratio at 0.75x — current liabilities exceed current assets
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Employees
94,000
Headquarters
DURHAM, NC
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.